人脐血CD133+血管内皮祖细胞的培养、鉴定与分化研究

目的探讨从人脐血中分离、体外培养CD133^＋血管内皮祖细胞（EPCs）的方法及其生长特性和鉴定。方法采用密度梯度离心法结合MACS分选法提取人脐血中CD133^＋细胞,进行流式细胞仪检测纯度,予EBM-2培养液接种培养,观察其生长特性;利用Dil-LDL及FITC-Lectin摄取实验、细胞免疫组织化学等进行鉴定。结果经流式细胞仪检测CD133^＋细胞平均占单核细胞的（1．13±0．10）％,磁珠分选所得CD133^＋细胞平均纯度为（91．45±1．04）％;CD133^＋细胞贴壁生长,可分化为梭形血管内皮细胞及形成集落;CD133^＋细胞培养过程中Dil-LDL及FITC-Lectin摄取阳性,双染阳性率为（95．83±1．72）％;CD133^＋细胞培养1周后经免疫组织化学检测CD34、Ⅷ因子阳性率分别为（95．83±2．23）％和（95．92±1．43）％,与人脐静脉内皮细胞比较差异无统计学意义;CD133^＋细胞体外培养4d、1周可形成小血管结构。结论免疫磁珠分选法可获取较高纯度CD133^＋血管内皮祖细胞,在生长因子作用下诱导其分化为成熟血管内皮细胞。     

基质细胞联合细胞因子对脐血CD133阳性细胞体外扩增和粘附分子表达的影响

CD133是新近发现的造血干细胞表面标志，众多的实验表明，脐血CD133^＋细胞能在体外得以扩增，我们选用脐血单个核细胞（MNC）作为培养的起始细胞，应用实验室已经建立的胚胎骨髓基质细胞联合细胞因子的造血细胞体外培养体系，研究脐血MNC中CD133^＋细胞在此培养体系的扩增效果，并检测CD133^＋细胞表面粘附分子CD44、CD62L的表达率，评估扩增后的脐血CD133^＋细胞的归巢能力。     

人脐血单个核细胞体外扩增后植入NOD/SCID小鼠重建多系造血

目的探讨人脐血单个核细胞（MNC）体外扩增后植入能力的改变，以及对NOD／SCID小鼠造血重建的影响。方法采用不同细胞因子组合对人脐血MNC进行短期无血清培养扩增，比较扩增后的效果及细胞凋亡的变化；将扩增6d后的人脐血MNC植入经半致死剂量照射的NOD／SCID小鼠体内，观察小鼠6周后的存活率和造血重建情况。结果人脐血MNC在干细胞因子（SCF）、酪氨酸激酶受体3配基（FL）、白细胞介素6（IL-6）和白细胞介素3（IL-3）细胞因子共同作用下，培养6～11）d获得最佳扩增效果，同时细胞表面膜联蛋白V（Annxin V）的表达明显减少；移植6周后有55．6％的小鼠存活，存活小鼠的骨髓、脾和胸腺细胞中均能检测出人类CD45、CD34、CD33、CD3和CDl9抗原，外周血提取的DNA可检测出人特异的Cart—Ⅰ基因和Alu基因。结论SCF＋FL＋IL-6＋IL-3细胞因子协同作用能有效扩增人脐血MNC，MNC扩增6d后可成功植入N（）D／SCID小鼠体内，并帮助小鼠重建多系造血。     

可溶性CD40L联合其他造血细胞生长因子体外扩增人脐血CD34+细胞

目的研究可溶性CD40L(sCD40L)对人脐血CD34 细胞体外扩增和集落形成的影响。方法用磁珠阳性分离纯化法分离脐血CD34 细胞;用造血干细胞体外悬浮培养、集落形成实验以及流式细胞仪检测等方法,观察应用sCD40L对脐血造血干细胞扩增、CD34 细胞增殖及造血集落形成的影响。结果sCD40L能显著增强干细胞因子(SCF)、白细胞介素3(IL-3)、促红细胞生成素(EPO)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)对脐血干细胞总数和CD34 细胞的扩增作用,并能促进造血集落,尤其是粒细胞-巨噬细胞集落形成单位(CFU-GM)的形成。sCD40L联合其他造血细胞生长因子对脐血CD34 细胞的扩增作用在培养的第7d最显著,当sCD40L浓度为40μg/L时,CD34 细胞的扩增倍数达8.23±1.26。结论sCD40L与SCF、IL-3、EPO、GM-CSF联合应用,对人脐血造血干细胞的体外扩增更为有效。     

骨髓间充质干细胞减轻体外扩增的脐血造血干细胞衰老的作用

目的 探讨骨髓间充质干细胞(MSC)对脐血造血干细胞体外扩增及抗细胞衰老的作用.方法 从新鲜脐血中分离出CD34+细胞,分别接种在含或不含MSC及细胞因子的培养体系中,取培养10d后的造血干细胞,分别用于细胞计数,集落分析,流式细胞仪检测表面标记,并对培养后的细胞进行β-半乳糖苷酶活性检测,采用实时定量聚合酶链反应(PCR)检测衰老相关基因p16INK4amRNA的表达.结果 体外培养10d后,MSC组、细胞因子组及MSC+细胞因子组对脐血总有核细胞(TNC)、CD34+细胞的体外扩增及克隆形成能力均有支持作用,以MSC+细胞因子组最为明显(P＜0.05),其扩增倍数分别达到(45.3±6.8)倍、(38.4±5.8)倍及(50.2±4.2)倍,但衰老细胞比例及p16INK4amRNA表达倍数则以MSC组最低,MSC+细胞因子组次之,细胞因子组两项指标均为最高(P＜0.05).结论 MSC能更好保护体外扩增的脐血造血干细胞,减少细胞衰老的发生,MSC+细胞因子是有效扩增脐血造血干细胞并保持细胞干性的更理想方法.     

脐血间充质干细胞的分离扩增及向成骨及脂肪细胞的分化

目的探讨新生儿脐血间充质干细胞（mesenchymal stem cells，MSCs）体外分离、纯化、扩增，以及向成骨及脂肪细胞定向诱导分化的方法与条件。方法无菌条件下收集新生儿脐血60～120ml，枸橼酸钠抗凝，以Ficoll—Hypaque淋巴细胞分离液密度梯度法、沉降红细胞后密度梯度法及CD34^＋免疫磁珠负选法分离单个核细胞（mononuclear cells，MNCs）。分离获得的MNCs采用L—DMEM培养基或Mesencult^TM培养基／10％胎牛血清进行MSCs培养传代，获得第3代集落生长细胞作流式细胞仪表面抗原测定，并向成骨及脂肪细胞定向诱导分化，成骨细胞钙沉积经茜素红染色鉴定，脂肪细胞胞浆油滴经油红染色鉴定。结果经沉降红细胞后分离的MNCs，使用Mesencult^TM培养基／10％胎牛血清培养成功率高，第3代可出现明显的集落生长，而另两种方法分离培养的细胞则难以形成集落；集落细胞表面抗原测定表达CD29、CD59、CD71而不表达CD34、CD45及HLA—DR等分子。成骨定向诱导分化的集落细胞经茜素红染色胞浆中出现有大量的钙沉积；成脂肪定向诱导分化的集落细胞油红染色示胞浆充满油滴空泡。结论新生儿脐血中可分离出MSCs，并可在体外进行培养扩增。以甲基纤维素沉降红细胞后密度梯度离心分离的MNCs培养较为有效，集落细胞表达基质细胞表面抗原，能够向成骨细胞及成脂肪细胞定向诱导分化。     

由脐血单个核细胞和富集的CD34+细胞扩增的造血干/祖细胞的生理功能比较

目的 探讨由脐血单个核细胞(MNC)和富集的CD34+细胞起始扩增所得的造血干/祖细胞在体内植入及造血重建的能力.方法 从人脐血中分离出MNC和CD34+细胞,在体外扩增7 d.将非肥胖糖尿病型重症联合免疫缺陷型(NOD/SCID)小鼠分为四组,在接受亚致死剂量铯源照射后,进行细胞移植,实验A组接受由MNC培养得到的CD34+细胞和CD34-细胞;实验B组接受由富集的CD34+细胞培养得到的CD34+细胞和CD34-细胞;阳性对照组接受从脐血新鲜分离的CD34+细胞和CD34-细胞;阴性对照组不接受细胞移植,仅输注相同体积的IMDM培养基.6周后处死存活的小鼠,取其骨髓、脾脏和外周血细胞,分别进行细胞表型分析、集落和人特异性基因的检测.结果 经过体外扩增,以富集的CD34+细胞起始培养者的细胞总扩增倍数为39.8倍,远高于以MNC为起始细胞者的1.88倍.移植6周后,所有接受细胞移植的小鼠均存活,存活小鼠的骨髓和脾脏细胞中均能检测到人源细胞(CD45+细胞)及人源的各系血细胞,实验A组各类细胞的含量稍高于实验B组,且接受细胞移植小鼠的骨髓和脾脏细胞中可检测出人特异的Alu序列.结论 与从脐血中新鲜分离的细胞相比,扩增后的造血干/祖细胞的体内植入能力有所下降,以MNC起始扩增的造血干/祖细胞体内植入能力优于以富集的CD34+细胞起始扩增者,但二者体内造血重建能力的差异不显著.     

脐血单个核细胞体外扩增的实验研究

目的 探讨含有细胞因子的无血清培养基对脐血单个核细胞(MNC)体外培养后的扩增情况和用于移植的安全性.方法 从新鲜脐血中分离出的MNC,在含细胞因子的无血清培养体系中培养.分别将培养前和培养第10天时的造血细胞进行细胞计数、细胞活力分析、集落分析、流式细胞仪检测表面标记、彗星试验分析DNA的损伤情况、无菌性分析及移植至NOD/SCID小鼠体内等项研究.结果 经过体外短期培养,脐血中MNC、CD34+、CD133+、CD34+CXCR4+及CD34+ VLA-4+细胞扩增倍数均比培养前增高(P<0.05);半固体培养基可支持多系集落的生长;培养前和培养第10天时脐血细胞DNA损伤率均低于5%;无菌性分析提示细胞未受污染.将体外扩增后的脐血造血细胞移植入NOD/SCID小鼠体内,与新鲜脐血移植相比,小鼠的存活时间及植入能力的差异均无统计学意义(P>0.05).结论 脐血造血细胞体外扩增是解决脐血造血细胞数量不足的有效方法.脐血造血细胞经短期培养能为造血干细胞移植提供安全而具植入能力的造血细胞.     

人脐血造血干/祖细胞的生物反应器大规模扩增及移植实验

目的 利用生物反应器大规模扩增人脐血造血干/祖细胞,并通过动物移植实验检验该方法的有效性.方法 采集抗凝脐血10份,分离出单个核细胞(MNC),分别进行生物反应器扩增培养和静态扩增培养.检测扩增前后细胞表面CD34、CD38、CD133、CD184和CD62L分子的表达,并进行造血干/祖细胞集落的培养.取非肥胖糖尿病重症联合免疫缺陷小鼠,以X射线照射后,分为4组,其中MNC组小鼠注射未经扩增培养的MNC;静态扩增组小鼠注射经过静态扩增培养的细胞;反应器扩增组小鼠注射经过生物反应器扩增培养的细胞;空白对照组小鼠注射生理盐水.移植后6周处死存活小鼠,收集骨髓细胞,检测其中CD45+、CD3+、CD19+和CD33+细胞的含量以及人特异的Cart-Ⅰ和Alu基因的表达.结果 生物反应器扩增前MNC为(1.2～2.8)×108个,扩增后为(3.7～12.6)×108个,扩增后的细胞数明显高于静态扩增培养者(P<0.01).经生物反应器扩增后所形成的红系集落形成单位、粒-巨噬细胞集落形成单位数明显高于经静态扩增者(P<0.05).移植6周后,空白对照组小鼠均死亡,MNC组存活率为35%,静态扩增组存活率为30%,反应器扩增组存活率为62.9%,后者明显高于前二者(P<0.05).各组存活小鼠骨髓细胞中均检测到Alu基因和Cart-Ⅰ基因的表达以及人源CD33+、CD45+、CD3+及CD19+细胞.结论 利用生物反应器可大规模扩增人脐血造血干/祖细胞,所得细胞能植入小鼠体内,并能获得造血功能重建.     

骨髓基质细胞共培养体系促进人脐血CD133+细胞的体外扩增

目的探讨来自白血病患者骨髓细胞的基质细胞层建立的扩增体系体外扩增人脐带血造血干/祖细胞的可行性。方法应用白血病患者缓解期骨髓基质细胞,结合造血细胞生长因子体外扩增人脐带血CD133 细胞(实验组),对扩增细胞的免疫表型、集落形成能力等生物学特性进行动态观察,并与单独应用造血细胞生长因子的常规扩增(对照组)进行比较。结果基质细胞层上接种的细胞易于收集;实验组在扩增各时间点的有核细胞数(NC)明显高于对照组,而且有核细胞中CD34 细胞、CD133 细胞、CD34 CD38-细胞以及CD34 CD133 细胞的比例也明显高于对照组;实验组扩增各时间点有核细胞各种集落的种植率明显高于对照组,有核细胞、CD34 细胞、CD133 细胞、CD34 CD38-细胞以及细胞集落的扩增倍数明显高于对照组。结论含有基质细胞的扩增培养体系,不仅可以加速人脐带血造血干/祖细胞的体外扩增,而且可以延缓造血干/祖细胞的分化。     

Ex vivo expansion and transplantation of hematopoietic stem/progenitor cells supported by mesenchymal stem cells from human umbilical cord blood

Human mesenchymal stem cells (MSCs) are multipotential and are detected in bone marrow (BM), adipose tissue, placenta, and umbilical cord blood (UCB). In this study, we examined the ability of UCB-derived MSCs (UCB-MSCs) to support ex vivo expansion of hematopoietic stem/progenitor cells (HSPCs) from UCB and the engraftment of expanded HSPCs in NOD/SCID mice. The result showed that UCB-MSCs supported the proliferation and differentiation of CD34+ cells in vitro. The number of expanded total nucleated cells (TNCs) in MSC-based culture was twofold higher than cultures without MSC (control cultures). UCB-MSCs increased the expansion capabilities of CD34+ cells, long-term culture-initiating cells (LTC-ICs), granulocyte-macrophage colony-forming cells (GM-CFCs), and high proliferative potential colony-forming cells (HPP-CFCs) compared to control cultures. The expanded HSPCs were transplanted into lethally irradiated NOD/SCID mice to assess the effects of expanded cells on hematopoietic recovery. The number of white blood cells (WBCs) in the peripheral blood of mice transplanted with expanded cells from both the MSC-based and control cultures returned to pretreatment levels at day 25 posttransplant and then decreased. The WBC levels returned to pretreatment levels again at days 45-55 posttransplant. The level of human CD45+ cell engraftment in primary recipients transplanted with expanded cells from the MSC-based cultures was significantly higher than recipients transplanted with cells from the control cultures. Serial transplantation demonstrated that the expanded cells could establish long-term engraftment of hematopoietic cells. UCB-MSCs similar to those derived from adult bone marrow may provide novel targets for cellular and gene therapy.     

体外扩增的脐血细胞移植于BALB/C小鼠的实验研究

目的　探讨经体外扩增的脐血造血细胞对小鼠造血重建功能的影响 ,寻求脐血用于成人移植的可行方法。方法　将经致死剂量γ射线照射后的BALB/C小鼠 ,随机分为 4组 ,每组 10只。A组 :每只移植 2 .5× 10 6个新鲜脐血细胞 ;B组 :每只分别移植 1.2 5× 10 6个新鲜脐血细胞和 1.2 5×10 6个扩增培养 1周的脐血细胞 ;C组 :每只移植 2 .5× 10 6个扩增培养 1周的脐血细胞 ;D组 :每只仅输注 0 .5ml生理盐水。比较各组造血重建的差别。结果　在脐血细胞移植后第 13d ,A组存活 5只(5 0 % ) ,B组 8只 (80 % ) ,C组 6只 (6 0 % ) ,D组全部死亡。B组小鼠的死亡率最低。脐血细胞移植后 14d ,小鼠的WBC已开始回升 ,B组与C组的恢复明显较A组快 ,P <0 .0 5。结论　混合移植新鲜的和体外培养 1周的脐血造血细胞 ,可能是脐血移植的较好办法。     

Quantification and Immunophenotypic Characterization of Bone Marrow and Umbilical Cord Blood Mesenchymal Stem Cells by Multicolor Flow Cytometry

In recent years, mesenchymal stem cells (MSC) have been attracting the greatest interest in the regeneration of injured tissues, autoimmune diseases, and transplantation of hematopoietic progenitor cells. Bone marrow (BM) represents the major source of MSC; however, umbilical cord blood (UCB) MSC has some advantages over BM, such as the higher differentiation capability and noninvasive collection methods. We sought to establish a 7-color, single-tube flow cytometric assay to quantify MSC in fresh tissues, namely BM and UCB, based on phenotypic markers of these cells. Moreover, we evaluated the differential expression of these markers in BM and UCB MSC. We used 5 UCB samples and 5 BM samples obtained from individuals without hematologic disease. To characterize MSC we used the following combination of monoclonal antibodies: CD71-FITC; CD105-PE; CD184-PE-Cy5; CD34-PE-Cy7; CD133-APC; CD45-APC-H7; CD44-Pacific blue, acquiring at least 1 million nucleated cells. We observed a greater number of BM MSC when compared with UCB MSC as well as some differences in the expression of some MSC antigens, particularly CD105 and CD44. Based on our preliminary results, phenotypic identification of MSC by flow cytometry is possible using a 7-color, single-tube assay. However, culture assays after sorting of cells characterized in this study are required to prove that they correspond to MSC.     

归芪合剂在小鼠骨髓移植后造血重建中的作用

目的探讨归芪合剂对小鼠骨髓移植后造血重建的影响。方法将BALB/c小鼠随机分为骨髓移植对照组(对照组)和骨髓移植归芪治疗组(归芪组)。对照组和归芪组的小鼠骨髓移植后,立即分别经胃饲生理盐水和归芪合剂0.4 ml,2次/d,直至小鼠处死为止。移植后第7、14、21 d时分别处死小鼠,计数其外周血白细胞、红细胞、血小板及骨髓单个核细胞,并作骨髓组织学观察。采用半定量逆转录聚合酶链反应(RT-PCR)和免疫组织化学方法检测小鼠骨髓单个核细胞CD44 mRNA基因的表达水平和骨髓组织中CD44的蛋白表达水平。结果归芪组骨髓移植后第7、14、21 d外周血细胞和骨髓单个核细胞计数,骨髓组织造血面积及巨核细胞计数,骨髓CD44 mRNA和蛋白表达水平均显著高于对照组(P<0.05或P<0.01)。结论归芪合剂能促进小鼠骨髓移植后骨髓造血重建,其机制可能是通过增强骨髓粘附分子CD44的表达水平实现的。     

人脐血造血干/祖细胞的磁力搅拌悬浮培养及移植实验

目的 探讨磁搅拌大规模培养体系对人脐血造血祖细胞的扩增效果以及扩增的人造血祖细胞植入动物体内后的造血重建情况.方法 从新鲜抗凝脐血中分离出单个核细胞(MNC),以添加干细胞因子、酪氨酸激酶受体3配基及血小板生成素的无血清培养体系进行培养.静态扩增组的细胞置于T25培养瓶中培养,磁搅拌悬浮扩增组(磁搅拌扩增组)的细胞采用Celstir装置进行培养,培养体系为50～100 ml.培养7 d后进行细胞计数、集落培养检测和细胞表面分子表达的测定.以不进行培养者为对照组.非肥胖糖尿病重症联合免疫缺陷(NOD/SCID)小鼠在接受2.5 Gy的亚致死剂量X射线照射后分别从尾静脉输入上述静态扩增组、磁搅拌扩增组和对照组的MNC(5×106个),另设不移植的空白对照组.观察小鼠的存活情况,6周后处死存活小鼠,检测骨髓细胞中CD34+细胞、CD3+细胞、CD19+细胞、CD33+细胞及CD45+细胞的含量以及人特异的Cart-Ⅰ和Alu基因的表达.结果 经过7天的培养,磁搅拌扩增组的造血祖细胞扩增倍数为(2.8±0.45)倍,明显高于静态扩增组的(2.1±0.48)倍(P<0.01).磁搅拌扩增组形成的红系集落、粒-巨噬细胞集落数均明显高于静态扩增组(P<0.05).静态扩增组扩增后的CD34+细胞、CD34+CD38-细胞和CD133+细胞含量均高于磁搅拌扩增组(P<0.05),而CD184+细胞和CD62L+细胞含量低于磁搅拌扩增组(P<0.01).移植后6周,对照组、静态扩增组和磁搅拌扩增组分别有3、4、5只小鼠存活,三组间两两比较,6周存活率的差异无统计学意义(P>0.05).存活6周的小鼠,其骨髓中能检人特异性CD34+细胞,以及CD3+细胞、CD19+细胞、CD33+细胞及CD45+细胞,也检测到人Alu基因和Cart-Ⅰ基因的表达.结论 磁搅拌培养能大规模扩增脐带血造血祖细胞,扩增的细胞能植入x射线照射的NOD/SCID小鼠,并重建其多系造血.     

T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation

BACKGROUND: We have previously shown that CD8 depletion or CD34 selection of peripheral blood stem cells (PBSC) reduced the incidence of acute graft-versus-host disease (GvHD) after nonmyeloablative stem-cell transplantation (NMSCT). In this study, we analyze the effect of CD8 depletion or CD34 selection of the graft on early T-cell reconstitution. METHODS: Nonmyeloablative conditioning regimen consisted in 2 Gy total-body irradiation (TBI) alone, 2 Gy TBI and fludarabine, or cyclophosphamide and fludarabine. Patients 1 to 18 received unmanipulated PBSC, patients 19 to 29 CD8-depleted PBSC, and patients 30 to 35 CD34-selected PBSC. RESULTS: T-cell counts, and particularly CD4+ and CD4CD45RA+ counts, remained low the first 6 months after nonmyeloablative stem-cell transplantation (NMSCT) in all patients. CD34 selection (P<0.0001) but not CD8 depletion of PBSC significantly decreased T-cell chimerism. Donor T-cell count was similar in unmanipulated compared with CD8-depleted PBSC recipients but was significantly lower in CD34-selected PBSC recipients (P=0.0012). T cells of recipient origin remained stable over time in unmanipulated and CD8-depleted PBSC patients but expanded in some CD34-selected PBSC recipients between day 28 and 100 after transplant. Moreover, whereas CD8 depletion only decreased CD8+ counts (P<0.047), CD34 selection reduced CD3+(P<0.001), CD8+(P<0.016), CD4+ (P<0.001), and CD4+CD45RA+ (P<0.001) cell counts. T-cell repertoire was restricted in all patients on day 100 after hematopoietic stem-cell transplantation but was even more limited after CD34 selection (P=0.002). CONCLUSIONS: Despite of the persistence of a significant number of T cells of recipient origin, T-cell counts were low the first 6 months after NMSCT. Moreover, contrary with CD8 depletion of the graft that only affects CD8+ lymphocyte counts, CD34 selection dramatically decreased both CD8 and CD4 counts.     

Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs

BACKGROUND: This study examines the effects of the most commonly used graft-versus-host disease (GVHD) prophylactic drugs on inducing apoptosis and suppressor cell function of human umbilical cord blood (UCB) CD4+25+ Treg and CD4+25- cells. METHODS: Cyclosporin A (CSA), methylprednisolone (MP), methotrexate (MTX), and mycophenolic acid (MPA) were added to the final 6 days of expansion cultures of Treg or CD4+25- T-cells isolated from the same donor and each concurrently cultured under the same conditions. Cell viability was measured for CD4+25+ as compared to CD4+25- T-cells and Treg function was assessed. The effects of these immunosuppressive drugs, Treg cells, or both also were tested in a primary allogeneic mixed lymphocyte response (MLR) response. RESULTS: The cell viability percentages were lower for CD4+25- cells than for Treg cells when MP, MTX, or MPA was added for the last 6 days of an expansion culture. Under these interleukin (IL)-2 based expansion conditions, CSA had no effect. The addition of any of the four GVHD prophylactic agents to the expansion phase of culture did not reduce the MLR suppressive capacity of Treg cells. Overall MLR suppression was increased when Treg cells were added along with CSA and MP to a primary MLR culture, whereas MTX modestly reduced Treg suppression. CONCLUSION: These data indicate a general resistance of expanded UCB Treg cells to GVHD immune suppressive agents and support trials to test UCB Treg infusions under the cover of GVHD prophylactic drugs in hematopoietic cell transplantation.     

联合成骨细胞移植促进骨髓移植小鼠的造血功能重建

目的 探讨联合成骨细胞移植对骨髓移植小鼠造血功能重建的影响.方法 Balb/c小鼠60只,取其中18只制备移植用骨髓有核细胞和成骨细胞.将其余42只小鼠分为3组.单纯移植组:小鼠18只,仅进行骨髓移植(BMT);联合移植组:18只,进行BMT的同时每只小鼠输入成骨细胞2×106个;正常对照组:小鼠6只,不做任何处理,仅作为移植前的正常对照.移植组小鼠在全身照射(TBI)预处理后4 h经尾静脉注入骨髓细胞2×106个.移植后第7、14和21天,分别处死移植组小鼠6只,对小鼠的外周血细胞和骨髓单个核细胞(BMMNC)进行计数,采用流式细胞术测定BMMNC中CD34+细胞的百分比,使用HPIAS-1000高清晰度彩色病理图像系统测量骨髓造血组织面积,采用免疫组化染色法测定骨髓组织微血管密度(MVD).结果 移植后第7天,单纯移植组和联合移植组小鼠外周血细胞计数及BMMNC数均明显低于正常对照(P＜0.01).第21天时联合移植组小鼠白细胞、红细胞及BMMNC数明显恢复,血小板数已接近正常对照组;单纯移植组小鼠外周血细胞数和BMMNC数虽然有所恢复,但其恢复程度明显弱于联合移植组.移植后第7、14和21天,联合移植组外周血细胞计数及BMMNC数均明显高于同期单纯移植组(P＜0.01或P＜0.05).移植后第7、14、21天,单纯移植组和联合移植组小鼠骨髓造血组织面积、BMMNC中CD34+细胞百分比及骨髓组织MVD均明显低于正常对照组(P＜0.01),但联合移植组均高于同期单纯移植组(P＜0.01或P＜0.05).结论 联合成骨细胞移植能有效促进骨髓移植小鼠骨髓造血系统的重建.

Abstract：

Objective To explore the effects of cotransplantation with osteoblasts on hematopoietic reconstitution in mice after bone marrow transplantation (BMT). Methods The typical model of syngeneic BMT was established. 18 Balb/c mice were used to prepare the bone marrow nuclear cells and osteoblasts for BMT. The 42 Balb/c mice were randomly divided into 3 group:normal group (6 mice, without any treatment), the single BMT group ( 18 mice, given 2 × 106 bone marrow nuclear cells/each mouse) and the cotransplantation group of HSC with osteoblaats (18 mice,given 2 × 106 bone marrow nuclear cells and osteoblasts/each mouse). The following factors were measured on day 7, 14, 21 after BMT: peripheral blood cells, bone marrow mononuclear cells (BMMNC), the percentage of CD34+ cells in BMMNC (assayed by flow cytometry), the hematopoietic tissue changes (detected by HPIAS-1000 image analysis system) and micro vascular density (MVD) of bone marrow tissue (with immunohistochemistry). Results The levels of periphral WBC, RBC, PLT, BMMNC in the contransplantation group were higher than those in the single BMT group (P＜0. 01 or P＜0. 05). In the contransplantation group, the percentage of CD34+ cells in BMMNC, the hematopoietic tissue area and the MVD of bone marrow were also higher than the single BMT group on the 7th, 14th, 21st day after BMT(P＜0.01 or P＜0.05). Conclusion Cotransplantation with osteoblasts could significantly promote hematopoietic reconstruction in mice after BMT. Cotransplantation may represent a promising means of achieving higher engraftment rate after BMT.